Dr. Reddy's Laboratories Limited (ADR) (NYSE:RDY)
| CAPS Rating |
|
|---|---|
| Open | $32.57 |
| Previous Close | $32.73 |
| Daily Range | $32.32 - $32.58 |
| 52-Week Range | $28.75 - $39.37 |
| Market Cap | $5.49B |
| P/E Ratio | 20.60 |
| Dividend (Yield) | 0.23 (0.40%) |
| Volume | 152,253 |
| Average Daily Volume | 0 |
RDY
VS S&P 500 (SPY)
How do you think RDY will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
RDY Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
RDY News and Commentary
- 7 Hot Indian Stocks – Minyanville
- A Smarter Way to Invest in Emerging Markets: Dividends – The Motley Fool
- Dr. Reddy's Laboratories Beats Analyst Estimates on EPS – The Motley Fool
- UPDATE: Dr Reddy's Laboratories 3Q Net Profit Soars 88%; Tops View – SmartMoney
- Dr Reddy's Laboratories 3Q Net Profit Soars 88%, Beats Estimates – SmartMoney
- Dr Reddy's: Resolved US FDA Issue Over Promotion Of Generic Anticlotting Injection – SmartMoney
- Medicines Co. Settles with APP - Analyst Blog – NASDAQ
- Zacks #5 Rank Additions for Monday - Tale of the Tape – NASDAQ
- Zacks #5 Rank Additions for Thursday - Tale of the Tape – NASDAQ
- The Zacks Analyst Blog Highlights: Teva Pharmaceuticals, Mylan, Watson Pharma, Dr. Reddy's and Novar – NASDAQ
- Dr Reddy's Launches Medicines For Pain, Itchy Skin In India – SmartMoney
- 12 Healthcare Dividend Stocks With Best Future EPS Growth – Blog at The Motley Fool
- IsoRay's GliaSite Gets Final Nod - Analyst Blog – NASDAQ
- Pozen Inks $75 Million Royalty Deal for Treximet – The Motley Fool
- Workers End Strike At Dr Reddy's Laboratories South India Plant – SmartMoney
- Dr Reddy's Asks Local Authorities To Help Resolve Labor Problems – SmartMoney
- Here's 1 Reason Pfizer Looks Weak – The Motley Fool
- Dr Reddy's 2Q Consolidated Net Profit Rises 7.3%, Beats View – SmartMoney
- FDA OKs Generics Of Zyprexa For Bipolar Disorder, Schizoprenia – SmartMoney
- Checking the Quality of Perrigo's Growth – The Motley Fool
RSS Headlines
Fool UK
